Introducing Next-Gen Actionable MRD

• Flexibility in baseline profiling – tissue or liquid biopsy

• Ultra-sensitive MRD detection – 0.005% LOD

• Tracking up to 50 personalized mutations, including fusions

• Detecting 500 actionable mutations

• Including genome-wide copy number changes

Product details

CLIA Validated ATLAS

Baseline Profiling

Blood, Urine, or Tissue
Low Input of Predicine Assays

Multi-Dimensional MRD Detection

Mutations, Fusions, and Copy Number Changes

Ultra Sensitivity

0.005% Limit of Detection

Actionable MRD

500 actionable mutations

Sample types


Sample requirements

20 ml of blood
8 ml of plasma
40 ml of urine
30-60 ng of cfDNA

Turnaround time

10 days

See the Unseen with PredicineBEACON™

PredicineBEACON™ is designed for ultra-sensitive MRD detection to address the following clinical questions beyond the capacity of conventional MRD assays:

  1. If tumor tissue is not available, can we do MRD using liquid biopsy at baseline?
  2. Can we track MRD by including fusion and copy number changes, beyond tracking mutations alone?
  3. If the cancer has recurred, are there any actionable mutations to guide future treatment options?

MRD Detection Unbounded by Baseline Sample Availability

MRD detection with PredicineBEACON™ is different from conventional MRD assays because it is not limited by baseline sample availability.  If available, baseline samples can be assessed using patient’s blood, urine or tissue. If a baseline sample is unavailable, monitoring the recurrence or progression of cancer can be achieved with a simple blood draw or urine sample with our tissue-agnostic approach.  


We offer pilot program grants to select biopharma and academic partners to empower translational research and clinical studies. To initiate a study, contact us via the form below.

Contact us

If you have any questions or need assistance, complete this form and we will respond within 24 hours.